They made the right moves to beat odds and triumph

May 31, 2009


NEW DELHI: Kanav Aggarwal probably visited his doctor more often than his school. But when he scored 81.8% in his class X Boards on Friday, his
parents and teachers were pleasantly surprised. Kanav, a student of Salwan Public School (afternoon), suffers from thalassemia. Three years ago, he also fell prey to ostoeporosis.

However, the 15-year-old continued school in between his blood transfusion sessions. “I could go to school only three or four days in a week. But my teachers and parents helped me,” said Kanav, who got 45 minutes extra to complete his paper. “We took up Kanav’s case with CBSE so that he could get extra time. Kanav was ready to study at odd hours and our teachers were there to give him extra classes,” said his school principal Rima C Ailawadi.

According to his mother Ritu Aggarwal, Kanav’s schooling was a tough challenge. “Kanav wants to become a scientist or animator. We thought he would have to take commerce but now that he has scored well, we may let him take science,” she said.

Kanav is not alone. Kanika Saxena from Apeejay, Pitampura, scored 80.2% in the class X Boards against all odds. She cannot walk because of spinal muscular atrophy and is wheelchair-bound. But she is also a chess player with an international ranking of 165. She said she managed to score well without any coaching at all. “I studied under difficult circumstances. I lost my father in October last year. In December, my grandfather died. It was very important to keep myself motivated,” she said. Added her mother Archana: “The school helped with facilities like a ramp. She also got an hour extra in the Board exams.”

At Tagore International School, Vasant Vihar, four visually impaired students of class X Rinku Shekhawat, Indira Rawat, Awayamber Singh and S Shankar Reddy managed to score above 70%.

Law on Compulsory Thalassemia Test for Grade 9 Students Urged

May 31, 2009


DUBAI — Health officials have called for legislation making thalassemia 
test compulsory for Grade 9 students and its inclusion in the curriculum
 as a subject.

They have also sought provision of uniform treatment methods across the emirates. Thalassemia is a genetic blood disorder and affects one
 in 12 Emiratis.

A survey done in Dubai in 2006 revealed that only 45 per cent of the 6,400 respondents were aware of
 the disorder.  “This is the reason why we have drawn up recommendations that are being put up to the Minister of Health for action,” said Saeed Jafar Al Awadhi, financial manager and member of Emirates Thalassemia Society.

“We are expecting a legislation to take shape in two years,” he added.

The Ministry of Health, Emirates Thalassemia Society and the Thalassemia Centre in Al Wasl Hospital are pushing the recommendations.

The recommendations also call for making compulsory premarital blood testing measures more stringent and raising awareness about the need for blood  donation.

“Grade 9 students are old enough to understand the need for testing and can also be educated on the disorder through a subject,” said Al Awadhi, explaining why the experts were pushing for testing in G9 students.  “They are old enough to take their own decisions.”

“Educating them on the complications that a child born to a thala-minor couple may make them cautious in choosing their life partners,”
he  explained.  A school health official said that though medical tests were being carried out on school children, none of them tested for thalassemia.

“Tests are done on G1, 5 and 9 students but we only do a complete blood count,” said  Dr Fawzia Al Jeziri, director of School Health, Ministry of Health. “If a child has a low blood count, he is sent for further testing,” she says, adding that a thalassemia-only test will detect the disorder early on. As prevention, the UAE laws call for compulsory pre-marital testing for national couples. However, since the law came into effect two years ago, only two couples called off their marriage after both were discovered with thalassemic traits, said Al Awadhi. “Most couples are bypassing this rule and may get their marriage certificates registered in emirates that are lax in their rules,” said Al Awadhi.

Awareness Drives Not Successful Yet

May 31, 2009


The Thalassemia Centre at Al Wasl Hospital saw at least 300 new cases last year, says Dr Essam Dohair, who is also the coordinator at the centre. “We already have a 100 per cent occupancy rate and 450 patients at the centre require regular blood transfusion (at least once in a month),” he said.

Patients at the centre require 16,000 units of blood in a year for transfusion.

“We need similar treatment and education methods across the emirates,” said Dr Dohair, adding that the centre also receives patients from the across the GCC.

Ruling out expansion, the centre has no option to meet the needs of the patients, the expert said.

“Treatment is already expensive and expansion means more spending on beds and staff,” he added.

Awareness and education is the key to prevention, he pointed out.

StemCyte, Inc. Reaches 1,000th Cord Blood Stem Cell Shipment for Transplant Milestone

May 31, 2009


COVINA, Calif., May 28 /PRNewswire/ — StemCyte, Inc., a privately held cord blood bank and stem cell therapeutics company, recently released their 1,000th cord blood stem cell shipment for transplant. This marks another landmark in the company’s rapid growth as one of the world’s leading providers of quality, prescription cord blood stem cell product.

(Photo: )

StemCyte will announce this major milestone at the 7th Annual International Umbilical Cord Blood Transplantation
Symposium in Los Angeles June 5-6, 2009.

“When StemCyte was founded in 1997, there were not even 1,000 cumulative cord blood transplants
worldwide. I am especially proud of the progress we have made during this time,” says Dr. Robert Chow, StemCyte Founder.

StemCyte has now provided prescription cord blood product to over 180 transplant centers worldwide in five continents and is a trusted name among transplant physicians. With both public and private banks in the U.S., India and Taiwan, StemCyte has emerged as a global leader in cord blood banking.

Cord blood stem cells have become a viable option to treat a variety of illnesses including leukemia, lymphomas, Autoimmune diseases and Genetic Blood disorders such as Thalassemia sickle-cell disease.

“With over 20 years of human safety and efficacy data, umbilical cord blood stem cells
are emerging as a prime source of stem cells for the field of regenerative medicine, which is the repair of injured tissues, nerves and organs. Research and clinical studies are increasing at an incredible pace and this will result in the treatment of some of the most devastating diseases. StemCyte’s large library of HLA typed product as well as our experience and expertise in this field will position us very well to take advantage of these emerging therapies,” explains StemCyte’s CEO Ken Giacin.

In 2008, StemCyte, Inc. signed two research and licensing agreements for human umbilical cord blood stem cell treatment for spinal cord injury, stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, ALS, and other problems of the central nervous system. The initiatives are being developed by Professor Wise Young M.D., Ph.D. at Rutgers the State University, New Jersey and Professor John Lin M.D., Ph.D. at China Medical University Hospital, Taiwan.

About StemCyte

StemCyte, Inc. is a global leader in stem cell therapeutics with a marketed umbilical cord blood stem cell transplantation
product. The company’s proprietary plasma-depleted cord blood stem cell products have been used to cure hundreds of patients with life-threatening diseases. With its partners, StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies and has the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world. The company operates one of two, and the only commercial cord blood bank in the world, dually accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). StemCyte is the only private company contracted by the Federal Government to establish a National Cord Blood Inventory. For more information, visit

Beta Thalassemia Testing

May 31, 2009


G7 HPLC Analyzer Beta-Thalassemia Testing Mode Provides HbF and HbA2 measurement and Hemoglobinopathy Screening

South San Francisco, CA (TOSOH) May 26, 2009 — Today, the measurement of hemoglobin A1c (HbA1c) is widely performed as a routine test using automated High Performance Liquid Chromatography (HPLC) with a short assay time. HPLC testing ( instruments are no longer solely dedicated for HbA1c testing. They are also used for HbF and HbA2 measurement and hemoglobinopathy screening.

Tosoh launched the Beta-thalassemia testing mode on the G7 in 2002 to provide high separation quality at an analysis time of 7.5 minutes per test. The G7 beta thalassemia testing mode quantifies HbF and HbA2 and provides presumptive identification of hemoglobin variants that cause hemoglobinopathies. The identification of hemoglobinopathy carriers is crucial since children born to these parents have a 25% chance of acquiring the disease.

The G7 HPLC Analyzer uses non-porous ion-exchange HPLC for rapid, accurate, and precise separation of the hemoglobin fractions. Analysis is carried out without any off-line specimen pretreatment. Separation is achieved by utilizing differences in ionic interactions between the cation exchange group on the column resin surface and the various hemoglobins and hemoglobin components.

Due to the increase in immigration of different ethnic groups, it is becoming more important to diagnose disorders of hemoglobin chain synthesis. Alternative methodologies for adequate presumptive identification usually require a combination of at least two techniques, one qualitative and one quantitative. Tosoh’s G7 beta thalassemia testing ( mode is the methodology of choice in today’s laboratories because you can efficiently obtain both qualitative and quantitative information at the same time.

For more information on Tosoh G7 HPLC Analyzer for HbA1c and Beta thalassemia testing, go to Tosoh Bioscience at

HemaQuest Initiates Clinical Trials in Sickle Cell Disease and Beta Thalassemia

May 31, 2009


Venture-backed Firm Seeks Safe and Effective Therapy for Common Life-threatening Genetic Disorders of Hemoglobin

05.27.2009 – SEATTLE – HemaQuest Pharmaceuticals announced today that it has initiated clinical trials of HQK-1001 in the treatment of patients with sickle cell disease and beta thalassemia. These two clinical trials are intended to evaluate safety and provide proof of concept clinical data in patients with these serious and life-threatening chronic illnesses.

“Our team is excited to have the opportunity to work with some of the leading clinical investigators to test HQK-1001 in sickle cell disease and beta thalassemia,” said Ron Berenson, M.D., President and Chief Executive Officer of HemaQuest. “There is a pressing need for new drugs to treat these disorders, which cause significant morbidity and early mortality. The goal of our clinical trials is to have sufficient data to move HQK-1001 into advanced clinical studies.”

Each of these blinded, placebo-controlled studies will assess the safety of HQK-1001 and evaluate indicators of therapeutic activity, including several measures of fetal globin, one of the drug’s primary targets. Increases in fetal globin correlate with improved clinical outcomes in patients with these hemoglobin disorders. The trial in sickle cell disease is being conducted at approximately 10 centers in the U.S. The trial in beta thalassemia is being conducted in Thailand, where there is a high incidence of this disease.

To date, HQK-1001 has been evaluated in 55 healthy human subjects in 2 clinical studies. In the first study, 24 subjects were treated with single doses of HQK-1001 at 4 dose levels. The second study was conducted in 41 healthy human subjects, who were treated with 14 consecutive days of HQK-1001 at 3 dose levels. HQK-1001 was well-tolerated at all dose levels and there were no serious adverse effects in the two studies. Plasma drug levels associated with in vitro biological activity were achieved in both studies.

About HQK-1001

HQK-1001 belongs to a class of compounds originally discovered at Boston University and licensed to the company. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal globin expression in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia. HQK-1001 is an orally administered SCFAD, which has shown potent effects on fetal globin induction and red blood cell production in the laboratory and relevant animal models. Additionally, the company has received orphan drug designation for HQK-1001 in the United States and Europe for both sickle cell disease and beta thalassemia.

About Sickle Cell Disease and Beta Thalassemia

Sickle cell disease is a genetic disorder affecting the beta globin chain of adult hemoglobin, resulting in distorted, rigid sickle red blood cells, which block blood vessels. The resulting lack of oxygen causes acute episodes of pain (pain crises), lung injury (acute chest syndrome) and is associated with strokes. Chronic damage occurs in many organs. The only drug available to treat the disease is a cancer chemotherapy drug, hydroxyurea, which has potential risks for patients. The lifespan of sickle cell patients is reduced in the U.S, where there are approximately 75-80,000 patients.

Beta thalassemia is a prevalent blood disease worldwide in which patients are unable to produce normal amounts of beta globin, which results in severe anemia. The primary treatment, red blood cell transfusions, leads to iron overload that damages many organs and requires treatment with iron chelating drugs. There is early mortality in patients with this disease is in the U.S. today.

About HemaQuest Pharmaceuticals

HemaQuest Pharmaceuticals, established in late 2007, is a biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary SCFAD technologies to treat hemoglobin diseases. HemaQuest is also developing other SCFADs that could prove useful in treating other hematologic disorders. The company’s investors include De Novo Ventures, Forward Ventures, and Lilly Ventures.

For More Information
Jerome Lyons
T: 206.826.9900
jlyons (at)

Mandatory Thalassemia Test Proposed For Those Intending To Wed

May 31, 2009


TAWAU, May 27 (Bernama) — A paediatrician here has proposed that the government make it mandatory for couples intending to tie the knot to be tested for thalassemia.

Dr Asmiati Abd Hamid, a paediatrician at the Tawau Hospital, said such a ruling was needed to control and prevent this genetic disease from spreading in the society.

She said such test could be carried out just like the mandatory HIV/AIDS test on couples which was currently in practice.

She made the suggestion at the launch of the Tawau Thalassemia Association by Sabah Assistant Finance Minister Datuk Tawfiq Abu Bakar Titingan.

Tawfiq, in his speech, said the government took a serious view of the disease because it was estimated that one in every 20 Malaysians was a Thalassemia carrier.

“Thus, the chances of our being carriers are five per cent. Five per cent is considered too high for a country. If neglected, it will burden future generations,” he said.

Thalassemia is a hereditary form of anaemia caused by faulty synthesis of haemoglobin.

Sickle Cell and Thalassemia patients can’t get proper treatment in Ontario

May 31, 2009


The Coalition to Save Our Young Adults called on the Ontario government Monday to fulfill its responsibility to the Sickle Cell and Thalassemia community by providing appropriate, comprehensive care for adult patients.

Since 2004, the Coalition has met on several occasions with hospital staff and government officials over the critical lack of space in the Thalassemia and Sickle Cell Clinic at Toronto General Hospital. In spite of repeated pledges to improve access to care and the level of service, one physician said, “The situation has gone from a crisis to a catastrophe.”

About 150 young adults over the age of 18 have no place to go for care. In the last five years, there have been around 15 Toronto area patient deaths, many of which the Coalition said were preventable. Ironically, many of these deaths were patients who had survived blood transfusions in the 1980’s that were contaminated or at risk for HIV and Hepatitis C.

Thalassemia is an inherited blood disorder in which the body is unable to make normal functioning hemoglobin, a protein in the blood required for the transportation of oxygen. Without regular blood transfusions, persons affected are unable to survive. A generation ago, patients rarely lived beyond childhood. Thanks to medical advances, they’re living healthy lives today, pursuing careers, continuing their education and raising families.

For years, Thalassemia patients in Canada had access to the highest standard of care in the world. Unfortunately, provincial funding for the only adult program in Toronto has been capped at 99 patients since the late 1990’s. Once pediatric patients turn 18, they have no place to go for treatment, can’t get the appropriate monitoring for adult care or the right support for emergency cases.

When adult patients develop complications, they are admitted to emergency departments at adult hospitals where their records and hospital files are not available. Physicians are often unaware of problems associated with Thalassemia, so complications develop into more serious conditions.

In 2003, the previous Toronto District Health Council, one of 16 District Health Councils (DHCs) in Ontario developed to advise the Ministry of Health and Long-Term Care on health system issues of importance to Toronto, concurred with the acute need for coordinated transition from pediatric to adult care.

“The situation has seriously deteriorated since that time evidenced by the death of our young patients,” said Riyad Elbard, president Thalassemia Foundation of Canada. “We have lost 15 patients, which we think many of them may be due to improper and inadequate care.”

Sickle cell disease (SCD) is a life threatening, hereditary blood disorder that causes malformation of red blood cells that become distorted when they transmit oxygen through the body. Instead of staying soft and round, cells become hard and shaped like a sickle or crescent moon, which can get clogged in blood vessels causing unpredictable episodes of excruciating pain that can last for weeks, tissue damage in any organ of the body or even a stroke.

Even with constant care, SCD can be fatal. Although there is no cure, blood transfusions and pain killers makes it possible for patients to better cope with complications. In Canada, SCD affects in 1 in 600 people of African descent.

In 1967, Sherman Moore was diagnosed with SCD at Toronto General Hospital, where he is a patient in the Thalassemia and Sickle Cell Clinic. As a result, he’s felt fortunate to be living in a country and a province with a good health care system. “When you have SCD and a crisis hits, you may often need emergency care,” said Moore. “This is a critical time where complications could set in if treatment is delayed.”

With longer wait times now, emergency staff having no access to medical records and doctors reluctant to administer narcotics for fear a patient may be a drug addict, a visit to an emergency room for a Sickler in crisis today can be a very trying and painful experience.

If a patient can be treated with narcotics, intravenous fluids and oxygen as soon as possible, it can prevent further complications from developing. If not, liver or kidney damage could occur. Patients might need blood transfusions. Despite the fact that Moore has spent many hours in emergency rooms waiting for treatment, he hasn’t experienced serious complications. But others have.

Moore admitted he’s seen a definite decline in emergency room service. Lately, he’s waited 4 or 5 hours to see a doctor. He’s learned to take painkillers with him so he can administer his own medication in the emergency room, if so required. Often, he said, treatment is delayed after seeing a health care professional because of concern that the patient could be a drug addict, due to the addictive nature of narcotics.

“That’s why we believe that adult patients with SCD and Thalassemia deserve the same level of care as those with other diseases,” said Moore. “Adult patients should have access to high quality comprehensive care provided in an adult setting.”

Moore is concerned and said, “It’s unacceptable that many young adults cannot get access to the adult clinic at Toronto General Hospital.”

Victoria Idowu also suffers from SCD and, like Moore, is a patient in the Thalassemia and Sickle Cell Clinic at Toronto General Hospital. For the first 16 years of her life, she said, “I received wonderful and excellent care at the Hospital for Sick Children.” But once she turned 19, Idowu left behind the security and safety of  SickKids.

For the last year, she’s been placed in an adult hospital that she said struggles to meet her needs due to the lack of funding (Idowu’s doctor is only able to see Sicklers four days a month.) and knowledge of how to treat adults suffering from this disease.

Based on her emergency room experiences, Idowu doesn’t feel the staff knows much about Sickle Cell and, therefore, doesn’t know how to treat patients in crisis. “We need help but they just don’t know how to give us the help we need,” she said. “When we’re in pain we need to be attended to promptly to prevent complications.”

In other settings, with both Thalassemia and SCD, emergency procedures would be in place in the emergency room. So if a patient comes in to emergency, the right procedure can be put into place, rather than challenging patients as to whether or not they’re actually in pain. With ongoing monitoring, however, patients are less likely to end up in emergency in the first place.

“We have Thalassemia patients that by the time they get to emergency, they’re having a heart crisis,” said Durhane Wong-Rieger, President and CEO, Anemia Institute for Research and Education. “They may not recover from that.”

Over the last 10 years, the Coalition, which includes the Anemia Institute for Research and Education, Thalassemia Foundation of Canada, Seed of Life, Sickle Cell Association of Ontario and Camp Jumoke, has met with hospitals, regional health authorities and with the Ministry of Health pleading for additional resources for adult Thalassemia and Sickle Cell care.

Although the response has often been sympathetic, there has been no increase in resources or positive action on the part of the hospitals or the Ministry. Meetings with the regional health authorities resulted in a report published in 2003, but no action on the basis of that plan.

“The deaths of young adults with these diseases in Canada are occurring at a time when other countries, with comparable populations but comprehensive care programs, have had few or no deaths,” said Wong-Rieger.

Yesterday, the Coalition called on the Minister of Health to honour the commitment made in 2005 and repeated in 2007 to adequately resource the adult Thalassemia and Sickle Cell clinic at Toronto General Hospital so that it can provide the highest level of comprehensive care, treatment and support to the approximately 150 adult patients now being denied access.

Patients outside the GTA and the province also have difficulty accessing comprehensive care. Janet Mulgrave, who is the president of the Sickle Cell Association of Ontario, said her group gets calls from all over Canada from people who can’t find proper care. In Ontario, the Association is trying to develop a Sickle Cell program in the Windsor area for a large patient population who don’t have access to proper care.

“We try to get patients care quickly thereby decreasing the chances of them going to an ICU (Intensive Care Unit) later on,” said Mulgrave. “Because we all know how expensive an ICU bed can be. So that’s the point of having access to care in a timely manner.”

Hospital Refuses Admission to Young Adults with Thalassemia and Sickle Cell Disease

May 31, 2009

Courtesy by:

TORONTO, May 25 /CNW/ – Young adults with thalassemia and sickle cell
diease have been trying for up to 10 years to gain admission to the only adult
hospital program in central and southwestern Toronto specialized to treat
their blood disorders. Since 1999, the Toronto General Hospital (TGH) has
restricted the inherited blood disorders program to 99 patients requiring
blood transfusions. As a result, about 150 young adults with complex disorders
receive blood transfusions at the Hospital for Sick Children but no adult

“For 18 years, you receive wonderful care. Suddenly you’re told there’s
no room for you in the adult program, so you get transfusions at one place and
emergency care somewhere else,” said Victoria Ibowu, a 19-year-old living with
sickle cell disease who cannot access adult care. “And you know that the only
way you’ll get into the adult program is when someone there dies.”

Thalassemia and sickle cell disease are inherited blood disorders
characterized by misshaped red blood cells. As a result, there is a lack of
oxygen delivered to tissues and vital organs. Until recently, few people with
thalassemia or sickle cell disease survived to adulthood. But thanks to
advances in treatment, many are now living into their 50s and beyond. But the
program at TGH, once considered among the best in the world, is severely
under-resourced. In their 2003 report, the Toronto District Health Council
called it “the price of success.” They concurred that it was inappropriate for
adult patients to be cared for in a children’s institution and that the lack
of resources posed a serious risk to adult patients. They called for the
immediate addition of health human resources to bring the program to an
appropriate level of care.

Over the past several years, about 15 young adults with thalassemia or
sickle cell disease have died, often of preventable causes. Most had survived
a blood supply in the 1980s that was at high risk for contamination with HIV
and hepatitis C. They died, not because of contaminated blood, but of
something more tragic: the lack of resources for adult care.

In 2004, after meetings with the patient community, the provincial
government committed to bringing the level of care for adult patients up to
the standards for the pediatric program. But little has changed. In the words
of one physician, the situation has gone from “a crisis to a catastrophe.”

Call for Immediate Action

Today, representatives of the Coalition to Save Our Young Adults,
including patients and families affected by thalassemia and sickle cell
disease, gathered in the Main Legislative Building of Queen’s Park to call
upon the members of Ontario parliament to fulfill their commitment to ensure
quality healthcare for adults with thalassemia and sickle cell.

“We cannot afford to allow this pattern of premature and unnecessary
death to continue,” said Riyad Elbard, president of the Thalassemia
Foundation. “The lack of resources puts all Ontario patients with inherited
blood disorders at risk.”

The Coalition, which includes the Anemia Institute for Research and
Education, Thalassemia Foundation of Canada, Seed of Life, Sickle Cell
Association of Ontario, and Camp Jumoke, are calling upon the Toronto General
Hospital, the LHINs, and the Ministry of Health to assure appropriate funding
and human resources.

Durhane Wong-Rieger, president of the Anemia Institute and Chair of the
Coalition, called upon the Ministry of Health and the Toronto General Hospital
to respond to this “catastrophe” by ensuring that the approximately 150 adult
patients who have been denied access to the program at TGH are transferred as
soon as possible from the Hospital for Sick Children to the adult program,
with appropriate service provision.

“It is unconscionable that these children, with the support of their
parents and healthcare professionals, have managed to survive these very
difficult chronic diseases but now find themselves all grown up with nowhere
to go.”

AACC 2009: Advancements in Immunoassay and HPLC Testing from Tosoh at AACC 2009

May 31, 2009

Courtesy by:

At AACC 2009 in Chicago, IL, Tosoh Bioscience (Booth #3140) will be featuring advancements in immunoassay and HPLC testing. During the AACC 2009 Annual Meeting Show Dates (July 21 – 23), events from Tosoh Bioscience will include free educational seminars by David Plaut as well as Tosoh product demonstrations. Plaut’s annual AACC educational seminars are eagerly anticipated as a source of pertinent information from immunoassay and HPLC testing.

South San Francisco, CA (PRWEB) May 21, 2009 — At AACC 2009 in Chicago, IL, Tosoh Bioscience (Booth #3140) will be featuring advancements in immunoassay and HPLC testing. During the AACC 2009 Annual Meeting Show Dates (July 21 – 23), events from Tosoh Bioscience will include free educational seminars by David Plaut as well as Tosoh product demonstrations. Plaut’s annual AACC educational seminars are eagerly anticipated as a source of pertinent information from immunoassay and HPLC testing. Also, Plaut provides immunoassay and HPLC case studies for reference. David Plaut will give free CDs of his seminar information to attendees.

There will also be excitement revolving around the Tosoh product line at AACC 2009, as Tosoh will be introducing a new analyzer for immunoassay testing: the AIA-2000 Automated Immunoassay Analyzer. With a throughput of 200 tests per hour, the AIA-2000 provides all the speed and flexibility necessary to excel in high throughput laboratory testing environments. Expanded functionality has been added to the system, improving laboratory workflow and increasing walk away time.

Also for Immunoassay testing, the AIA-360 is a sophisticated system that fits in any lab environment. With a footprint of 16 X 16 X 21 inches and weighing approximately 60 lbs., the AIA-360’s compact design makes it ideal for physician office laboratories, work stations for small hospitals, STAT testing, such as cardiac panels, as well as a dedicated system for specialty testing. With a throughput of 36 tests per hour, the AIA-360 generates its first result in approximately 20 minutes. The cost effective system utilizes the same 10 minute ST reagents as Tosoh’s larger systems, making it the perfect back-up analyzer.

Tosoh’s AIA-600 II is a proven system and has earned the industry-wide reputation of high reliability for immunoassay testing. The analyzer provides big system features in a bench top analyzer. Fitting in just 30 inches of counter space, the AIA-600 II has a throughput of 60 results per hour including STAT assay results in ~18 minutes, making it an ideal solution for time-critical tests such as cardiac markers.

All Tosoh AIA immunoassay testing systems utilize the same Unit Dose Test Cup reagent format, ensuring consistent performance every time. With interchangeable reagents on all Tosoh systems, inventory management is easy and problem free. Transition from one system to another is seamless, ensuring consistent results and efficient, economical operation for the laboratory.

For HbA1c testing, Tosoh’s G8 HPLC Analyzer provides one of the industry’s lowest CVs of less than 2%. The NGSP certified instrument-reagent system utilizes the gold standard ion-exchange method for HbA1c testing to effectively monitor glycohemoglobin in diabetic patients. With a compact footprint of 21″w x 19″h x 20″d, the G8 fits easily in most laboratory environments. The G8 provides fast results with an HbA1c analysis time of only 1.6 minutes. Simple touch-screen operation, as well as automatic start-up and daily maintenance make the system extremely user-friendly.

The Tosoh G7 HPLC Analyzer can be used for both HbA1c and beta-thalassemia testing in one compact analyzer.  The system provides beta-thalassemia results in less than 8 minutes with quantification of HbF and HbA2.  Also, the NGSP certified G7 HPLC Analyzer delivers presumptive identification of HbS, C and D; as well as true separation of Labile and Stable A1c.

With the TRCRapid-160 (Research Use Only), Tosoh has responded to the growing need and acceptance of molecular diagnostic devices.  This accurate and full-featured platform delivers accelerated real-time RNA amplification and detection by combining two innovative technologies – the isothermal TRC reaction and the unique INAF fluorescence probe. This technology features much lower reaction times than seen with traditional real-time PCR.  This instrument has the potential to be used in many testing areas, such as infectious diseases, cancer markers and
environmental testing.

In 2009, Tosoh Bioscience, Inc. is celebrating 20 years in the diagnostic industry. Started in 1989 as Tosoh Medics, Inc., the company is committed to providing quality diagnostic systems and priority service to laboratory customers. TBI has sustained double digit growth over the past 8 years, surpassing the industry growth of ~ 4%, with 2008 being the most successful year to date. Sales of Tosoh Bioscience analyzers and assays have grown consistently throughout the years.

%d bloggers like this: